Abstract
Background: Immunization is the most effective way to prevent transmission of hepatitis B virus and hence the development of acute or chronic hepatitis B. End stage renal diseases (ESRD) patients have lower seroconversion rates compared with the subjects with intact renal function. Moreover, even after the completion of hepatitis B vaccination schedule , anti-HBs titer of responders was found to be low and decline logarithmically with time.
Study objectives: this study is to identify the effectiveness of Hepatitis B vaccine and its response in end stage renal disease patients on hemodialysis.
Patients and methods: A cross sectional study with analytic components was done on patients with end stage renal disease on dialysis who completed hepatitis B Vaccine in 4 doses and received hemodialysis in Al Shafaa center in Al Yarmouk Teaching Hospital during 2022.
Results: The study involved 150 patients on hemodialysis who complete the hepatitis vaccine doses, the mean age was 53.2 years,63.3% male and 36.7% female, duration of dialysis range from (1-7 years),most of them received 4 vaccine doses 56.7%, the response rate to HB Vaccine was;1)non responder whose anti HBs Ab titer less than 10 IU/Lwas33.3% .2)poor responder whose Anti HBs Ab titer between 10-100 IU/L was 20%.3)good responder with Anti HBs Ab titer more than 100IU/L was 46.7%. serum albumin had significant association with response to vaccine , while duration and quality of dialysis, number of vaccine doses, hemoglobulin and S. creatinine did not affect the response rate to vaccine.
Conclusion: Many factors affecting response to hepatitis B vaccine in hemodialysis patients , but a significant association was found between S. Albumin and the duration of last vaccine of patients with the response rate to hepatitis B vaccine.
Keywords
Main Subjects
)
